Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2positive non-breast advanced solid tumors.

被引：0
|
作者：
Wang, Jianzheng
Zhang, Baiwen
Cheng, Xiaojiao
Li, Qingli
Lv, Huifang
Nie, Caiyun
Chen, Beibei
Xu, Weifeng
Zhao, Jing
He, Yunduan
Tu, Shuiping
Chen, Xiaobing
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Dept Gastrointestinal Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Zheng zhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15064
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of pyrotinib for HER-2-positive breast cancer in the neoadjuvant setting: A systematic review and meta-analysis
    Ma, Qian
    Wei, Bai
    Wang, Bi-Cheng
    Wang, Ganxin
    Zhou, Xuan
    Wang, Yan
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [42] Pyrotinib in HER2-Positive local advanced or metastatic breast cancer patients: Results from a retrospective study in real-world setting
    Wang, Q.
    Chen, C.
    Wang, Y.
    Sun, S.
    Cheng, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S58 - S58
  • [43] Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study
    Hao, Li
    Dong, Jie
    Yu, Haiyang
    Chen, Jian
    Han, Xinghua
    Pan, Yueyin
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (10) : 2726 - +
  • [44] Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study
    Li, Chao
    Bian, Xiaoli
    Liu, Zhaoyun
    Wang, Xinzhao
    Song, Xiang
    Zhao, Wei
    Liu, Yansong
    Yu, Zhiyong
    CANCER MEDICINE, 2021, 10 (23): : 8352 - 8364
  • [45] A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
    Jin, N.
    Yin, Y.
    Li, W.
    Huang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [46] Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
    Zhang, Qiongwen
    He, Ping
    Tian, Tinglun
    Yan, Xi
    Huang, Juan
    Zhang, Zhang
    Zheng, Hong
    Zhong, Xiaorong
    Luo, Ting
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [47] Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study
    Yin, Sha
    Chi, Yajing
    Du, Yangyang
    Wang, Jingfen
    Shan, Changping
    Yi, Weiwei
    Shang, Mao
    Man, Xiaochu
    Tan, Qiaorui
    Li, Huihui
    CANCER MEDICINE, 2023, 12 (03): : 2333 - 2344
  • [48] Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience
    Tiwari, A.
    Gogia, A.
    Deo, S. V. S.
    Shukla, N. K.
    Mathur, S.
    Sharma, D. N.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 343 - 346
  • [49] A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors
    Zhang, Congjun
    Li, Jingjing
    Wu, Hongyang
    Huang, Wei
    Da, Liangshan
    Shen, Yuanyuan
    Sun, Guoping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] The efficacy and safety of anlotinib in refractory/recurrent/advanced pediatric solid tumors: A retrospective study.
    Lu, Suying
    Hong, Ye
    Chen, Huimou
    Wu, Liuhong
    Zhu, Jia
    Wang, Juan
    Sun, Feifei
    Zhen, Zijun
    Que, Yi
    Zhang, Lian
    Sun, Xiaofei
    Huang, Junting
    Zhang, Yizhuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345